Critical Limb Ischemia (CLI) Drug Development- Pipeline Analysis Report

Critical Limb Ischemia (CLI) Drug Development- Pipeline Analysis Report

  • April 2018 •
  • Report ID: 5389600 •
  • Format: PDF
Critical Limb Ischemia (CLI) is a catastrophic condition representing the most advanced phase of peripheral arterial disease. Patients witness strong blocking of the arteries, resulting in decreased blood flow thereby, resulting in acute pain, loss of tissues and claudication. The condition is a result of arteriosclerosis, which leads to extreme low arterial blood flow in lower limbs.
Lack of therapeutic options cause amputation being the current options and typical survival rates of amputations is below 30%. Diabetes, smoking and hypertension are the major risk aspects of the condition.
An estimated 1.8 million patients suffer from Critical Limb Ischemia worldwide, with an estimated market size of $10 to $12 billion.

Critical Limb Ischemia pipeline comprises of 27 active drugs under active development as of April 2018. Of these, 2 drugs are in Phase 1 and 16 drugs in phase 2, 2 drugs in Phase 3. Further, 6 drugs are in Pre-clinical stage and 1 drug in pre-registration stage.

43 companies are developing the pipeline for Critical Limb Ischemia. Of this, Rexgenero Ltd. has highest number of compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is Cell replacements.
One compound has been awarded FDA fast track status for Critical Limb Ischemia.

To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Critical Limb Ischemia (CLI) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Critical Limb Ischemia (CLI) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Critical Limb Ischemia (CLI) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

We are very sorry, but an error occurred.
Please contact if the problem remains.